Top 6 takeaways from Merck's R&D update
This article was originally published in Scrip
Big pharma and large biotech companies once again are considering mega-mergers to increase market value, but Merck & Co chairman and CEO Kenneth Frazier says the company will grow via research and development innovation as well as smaller acquisitions rather than through consolidation, so its R&D strategy is increasingly important (scripintelligence.com, 30 April 2014).
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.